Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT-AUT
- Development stage
- Unknown
- Lead developer
- Sant’Orsola-Malpighi University Hospital
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
CT-AUT is an experimental autologous cancer vaccine consisting of formalin-treated tumor cells derived from a patient's own metastatic renal cell carcinoma (RCC). As a cell-based immunotherapy, it is designed to expose the patient's immune system to a comprehensive array of autologous tumor-associated antigens. In clinical practice, CT-AUT is typically co-administered with ACHN-IL2, an allogeneic renal cell carcinoma cell line genetically modified to secrete interleukin-2 (IL-2), which acts as an immunostimulatory agent to enhance the T-cell and natural killer (NK) cell response against the tumor. This combination therapy has been investigated in Phase 3 clinical trials, primarily led by the Azienda Ospedaliera di Bologna, for the treatment of metastatic renal cell carcinoma, focusing on endpoints such as overall survival and quality of life.
- Other names
- autologous tumor cellsformalin-treated autologous tumor cells
Beyond the preview
Go deeper on CT-AUT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT-AUT.